Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine Combined With Levothyroxine in Euthyroid Women With Thyroid Antibody Positive and Unexplained Recurrent Pregnancy Loss
NCT06652113Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Nov 2024
- Primary completion
- Mar 2035
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of hydroxychloroquine in recurrent pregnancy loss (RPL) (2 arms), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Birth of a living child beyond 28 weeks. Started Nov 2024; status: recruiting.
02
Drugs
hydroxychloroquine
03
Conditions
recurrent pregnancy loss (RPL)
Beyond the preview
Go deeper on NCT06652113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06652113.